ASH Guidelines for the use of TPO-RAs in chronic ITP1
The American Society of Hematology (ASH) provides evidence-based recommendations to help inform treatment decisions for adult patients with immune thrombocytopenia (ITP).
In 2019, ASH published updated treatment guidelines for the management of ITP, informed by a comprehensive review of available clinical evidence and expert consensus. The guidelines emphasize limiting prolonged corticosteroid exposure when possible and recommend consideration of second-line therapies for patients with persistent or chronic ITP who are corticosteroid dependent or unresponsive.
TPO-RAs can be used as a second-line treatment for adults with ITP who are unresponsive to first-line therapies such as corticosteroids1
Short-term corticosteroid use is preferred over prolonged corticosteroid exposure in adults with ITP1*
Doptelet was not incorporated into the 2019 ASH guideline recommendations.
Access the full 2019 ASH guidelines for more information
Review comprehensive guidance to help inform ITP treatment decisions.
Doptelet was approved for use in chronic ITP in 2019. Inclusion in formal treatment guidelines is dependent on publication timelines, evidence review processes, and committee evaluation.
*Please refer to the full ASH guideline publication for complete recommendations, supporting evidence, and clinical context.
TPO-RA=thrombopoietin receptor agonist.
Considering Doptelet for your adult patients with chronic ITP?
See the data and patient results from the Doptelet clinical trials.
Image
- Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.